However, previous studies showed that fewer than 20% of advanced HCC patients achieved an objective tumor response in anti-PD-1 monotherapy, indicating that combination regimens—e.g., anti-PD-1 with an antiangiogenic therapy—might be better options for systemic treatment (7–9). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.